Genetic and epigenetic studies of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue SUPPL1, 2013, Pages 44-52

  Al Chalabi, Ammar ^a   Kwak, Shin ^b   Mehler, Mark ^c   Rouleau, Guy ^d   Siddique, Teepu ^e   Strong, Michael ^f   Leigh, Peter Nigel ^g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TOKYO   (Japan)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

ALS; Epigenetic; Familial ALS; Genetic; Modifier genes

Indexed keywords

PROTEASOME; UNTRANSLATED RNA;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CAUSE OF DEATH; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; EXON; FAMILY HISTORY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HETEROZYGOSITY; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; INTRACELLULAR TRANSPORT; MODIFIER GENE; MOLECULAR PATHOLOGY; NERVE FIBER TRANSPORT; ONSET AGE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA EDITING; RNA PROCESSING; STRESS; SURVIVAL; UBIQUITINATION; UBQLN2 GENE; GENETIC PREDISPOSITION; PATHOPHYSIOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; AXONAL TRANSPORT; DISEASE PROGRESSION; EPIGENOMICS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84877860468     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2013.778571     Document Type: Article

References (68)

1. Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry. 2011; 82: 623-7.
2. Al-Chalabi A, Fang F, Hanby MF, Leigh PN, Shaw CE, Ye W, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. Journal of Neurology, Neurosurgery, and Psychiatry. 2010; 81: 1324-6.
3. Andersen PM, Al-Chalabi A. Clinical genetics of amyo-trophic lateral sclerosis: what do we really know? Nature reviews. Neurology. 2011; 7: 603-15.
4. Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyo-trophic lateral sclerosis. Amyotrophic lateral sclerosis: offi cial publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. 2011; 12: 157-9.
5. Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Human Heredity. 2011; 71: 281-8. Epub 2011/08/19.
6. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet. 1955; 7: 277-318.
7. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996; 273: 1516-7.
8. Ott J. Estimation of the recombination fraction in human pedigrees: effi cient computation of the likelihood for human linkage studies. Am J Hum Genet. 1974; 26: 588-97.
9. Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Human Mutation. 2012. Epub 2012/07/04.
10. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62.
11. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde CV, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 572-4.
12. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, et al. TARDBP mutations in amyo-trophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. The Lancet Neurology. 2008; 7: 409-16.
13. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008; 319: 1668-72.
14. Kwiatkowski TJ Jr, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis. Science. 2009; 323: 1205-8.
15. Vance C, Rogelj B, Hortobagyi T, de Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009; 323: 1208-11.
16. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, et al. ANG mutations segregate with familial and'sporadic'amyotrophic lateral sclerosis. Nat Genet. 2006; 38: 411-3.
17. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010; 465: 223-6.
18. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011; 477: 211-5.
19. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011; 72: 257-68.
20. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72: 245-56.
21. Schymick JC, Scholz SW, Fung HC, Britton A, Arepalli S, Gibbs JR, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: fi rst stage analysis and public release of data. Lancet Neurology. 2007; 6: 322-8.
22. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, et al. Whole genome analysis of sporadic amyotrophic lateral sclerosis. The New England Journal of Medicine. 2007; 357: 775-88.
23. Cronin S, Berger S, Ding J, Schymick JC, Washecka N, Hernandez DG, et al. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet. 2008; 17: 768-74.
24. van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, van den Bosch L, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 29-31.
25. Chio A, Schymick JC, Restagno G, Scholz SW, Lombardo F, Lai SL, et al. A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2009; 18: 1524-32.
26. van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurology. 2007; 6: 869-77.
27. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, et al. Reduced expression of the kinesin-associ-ated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2009; 106: 9004-9.
28. van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al. Genome-wide association study identifi es 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009; 41: 1083-7.
29. Shatunov A, Mok K, Newhouse S, Weale ME, Smith B, Vance C, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology. 2010; 9: 986-94.
30. Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai SL, Myllykangas L, et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurology. 2010; 9: 978-85.
31. Kwee LC, Liu Y, Haynes C, Gibson JR, Stone A, Schichman SA, et al. A high-density genome-wide association screen of sporadic ALS in US veterans. PloS One. 2012; 7: 32768.
32. Simpson CL, Lemmens R, Mskiewicz K, Broom WJ, Hansen VK, van Vught PW, et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet. 2009; 18: 472-81.
33. Blauw HM, Al-Chalabi A, Andersen PM, van Vught PW, Diekstra FP, van Es MA, et al. A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Hum Mol Genet. 2010; 19: 4091-9.
34. Wain LV, Pedroso I, Landers JE, Breen G, Shaw CE, Leigh PN, et al. The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci. PloS One. 2009; 4: 8175.
35. Cronin S, Blauw HM, Veldink JH, van Es MA, Ophoff RA, Bradley DG, et al. Analysis of genome-wide copy number variation in Irish and Dutch ALS populations. Hum Mol Genet. 2008; 17: 3392-8.
36. Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, van der Zwaag B, et al. Copy number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurology. 2008; 7: 319-26.
37. Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, et al. The C9ORF72 expansion mutation is a common cause of ALSFTD in Europe and has a single founder. European Journal of Human Genetics: EJHG. 2012.
38. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology. 2012; 11: 323-30.
39. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010; 466: 1069-75.
40. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996; 14: 269-76.
41. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet. 1996; 14: 285-91.
42. Cancel G, Durr A, Didierjean O, Imbert G, Burk K, Lezin A, et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet. 1997; 6: 709-15.
43. Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012; 33: 630, e3-8.
44. Traynor BJ, Nalls M, Lai SL, Gibbs RJ, Schymick JC, Arepalli S, et al. Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population based cohort of ALS patients. Proc Natl Acad Sci U S A. 2010; 107: 12335-8.
45. Orsetti V, Pegoraro E, Cima V, d'Ascenzo C, Palmieri A, Querin G, et al. Genetic variation in KIFAP3 is associated with an upper motor neuron-predominant phenotype in amyotrophic lateral sclerosis. Neurodegenerative Diseases. 2011; 8: 491-5.
46. Fogh I, Rijsdijk F, Andersen PM, Sham PC, Knight J, Neale B, et al. Age at onset in SOD1-mediated amyotrophic lateral sclerosis shows familiality. Neurogenetics. 2007; 8: 235-6.
47. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008; 273: 67-9.
48. Lambrechts D, Storkebaum E, Morimoto M, del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifi er of amyotrophic lateral sclerosis in mice and humans and protects motor neurons against ischemic death. Nat Genet. 2003; 34: 383-94.
49. Millecamps S, Salachas F, Cazeneuve C, Gordon P, Bricka B, Camuzat A, et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. Journal of Medical Genetics. 2010; 47: 554-60.
50. Wills AM, Cronin S, Slowik A, Kasperaviciute D, van Es MA, Morahan JM, et al. A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology. 2009; 73: 16-24.
51. Veldink JH, Kalmijn S, van der Hout AH, Lemmink HH, Groeneveld GJ, Lummen C, et al. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology. 2005; 65: 820-5.
52. Kolb SJ, Sutton S, Schoenberg DR. RNA processing defects associated with diseases of the motor neuron. Muscle Nerve. 2010; 41: 5-17.
53. Strong MJ. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2010; 288: 1-12.
54. Lemmens R, Moore MJ, Al-Chalabi A, Brown RH Jr, Robberecht W. RNA metabolism and the pathogenesis of motor neuron diseases. Trends in Neurosciences. 2010; 33: 249-58.
55. Mehler MF. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Progress in Neurobiology. 2008; 86: 305-41.
56. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008; 454: 126-30.
57. Qureshi IA, Mattick JS, Mehler MF. Long non-coding RNAs in nervous system function and disease. Brain Research. 2010; 1338: 20-35.
58. Qureshi IA, Mehler MF. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat Rev Neurosci. 2012; 13: 528-41.
59. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009; 326: 1549-54.
60. Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ. Epigenetic regulation of motor neuron cell death through DNA methylation. The Journal of Neuroscience: the offi cial journal of the Society for Neuroscience. 2011; 31: 16619-36.
61. Laffi ta-Mesa JM, Bauer PO, Kouri V, Pena Serrano L, Roskams J, Almaguer Gotay D, et al. Epigenetics DNA methylation in the core ataxin-2 gene promoter: novel physiological and pathological implications. Hum Genet. 2012; 131: 625-38.
62. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Current Opinion in Neurobiology. 2011; 21: 904-19.
63. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004; 427: 801.
64. Kwak S, Kawahara Y. Defi cient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med. 2005; 83: 110-20.
65. Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium infl ux through AMPA receptors, selective in the spinal ventral gray of patients with amyo-trophic lateral sclerosis. Annals of Neurology. 1999; 46: 806-15.
66. Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. The Journal of Neuroscience: the offi cial journal of the Society for Neuroscience. 2010; 30: 11917-25.
67. Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010; 120: 75-84.
68. Kwak S, Nishimoto Y, Yamashita T. Newly identifi ed ADAR-mediated A-to-I editing positions as a tool for ALS research. RNA Biol. 2008; 5: 193-7.